Cell therapy for neonatal hypoxia-ischemia and cerebral palsy

Laura Bennet, Sidhartha Tan, Lotte Van Den Heuij, Matthew Derrick, Floris Groenendaal, Frank Van Bel, Sandra Juul, Stephen Back, Frances Northington, Nicola J. Robertson, Carina Mallard, Alistair Jan Gunn

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Perinatal hypoxic-ischemic brain injury remains a major cause of cerebral palsy. Although therapeutic hypothermia is now established to improve recovery from hypoxia-ischemia (HI) at term, many infants continue to survive with disability, and hypothermia has not yet been tested in preterm infants. There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor cells may have multiple beneficial effects on outcome after hypoxic-ischemic injury. Stem/progenitor cells have shown great promise in animal studies in decreasing neurological impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and method of administration remain surprisingly unclear, and some studies have found no benefit. Although cell-based interventions after completion of the majority of secondary cell death appear to have potential to improve functional outcome for neonates after HI, further rigorous testing in translational animal models is required before randomized controlled trials should be considered.

Original languageEnglish (US)
Pages (from-to)589-600
Number of pages12
JournalAnnals of Neurology
Volume71
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Cerebral Palsy
Cell- and Tissue-Based Therapy
Stem Cells
Ischemia
Induced Hypothermia
Hypothermia
Premature Infants
Brain Injuries
Cell Death
Randomized Controlled Trials
Animal Models
Hypoxia
Newborn Infant
Wounds and Injuries

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Bennet, L., Tan, S., Van Den Heuij, L., Derrick, M., Groenendaal, F., Van Bel, F., ... Gunn, A. J. (2012). Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Annals of Neurology, 71(5), 589-600. https://doi.org/10.1002/ana.22670

Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. / Bennet, Laura; Tan, Sidhartha; Van Den Heuij, Lotte; Derrick, Matthew; Groenendaal, Floris; Van Bel, Frank; Juul, Sandra; Back, Stephen; Northington, Frances; Robertson, Nicola J.; Mallard, Carina; Gunn, Alistair Jan.

In: Annals of Neurology, Vol. 71, No. 5, 05.2012, p. 589-600.

Research output: Contribution to journalArticle

Bennet, L, Tan, S, Van Den Heuij, L, Derrick, M, Groenendaal, F, Van Bel, F, Juul, S, Back, S, Northington, F, Robertson, NJ, Mallard, C & Gunn, AJ 2012, 'Cell therapy for neonatal hypoxia-ischemia and cerebral palsy', Annals of Neurology, vol. 71, no. 5, pp. 589-600. https://doi.org/10.1002/ana.22670
Bennet L, Tan S, Van Den Heuij L, Derrick M, Groenendaal F, Van Bel F et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Annals of Neurology. 2012 May;71(5):589-600. https://doi.org/10.1002/ana.22670
Bennet, Laura ; Tan, Sidhartha ; Van Den Heuij, Lotte ; Derrick, Matthew ; Groenendaal, Floris ; Van Bel, Frank ; Juul, Sandra ; Back, Stephen ; Northington, Frances ; Robertson, Nicola J. ; Mallard, Carina ; Gunn, Alistair Jan. / Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. In: Annals of Neurology. 2012 ; Vol. 71, No. 5. pp. 589-600.
@article{c2545b0f3ca74dc0a09871a0eee2f1d1,
title = "Cell therapy for neonatal hypoxia-ischemia and cerebral palsy",
abstract = "Perinatal hypoxic-ischemic brain injury remains a major cause of cerebral palsy. Although therapeutic hypothermia is now established to improve recovery from hypoxia-ischemia (HI) at term, many infants continue to survive with disability, and hypothermia has not yet been tested in preterm infants. There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor cells may have multiple beneficial effects on outcome after hypoxic-ischemic injury. Stem/progenitor cells have shown great promise in animal studies in decreasing neurological impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and method of administration remain surprisingly unclear, and some studies have found no benefit. Although cell-based interventions after completion of the majority of secondary cell death appear to have potential to improve functional outcome for neonates after HI, further rigorous testing in translational animal models is required before randomized controlled trials should be considered.",
author = "Laura Bennet and Sidhartha Tan and {Van Den Heuij}, Lotte and Matthew Derrick and Floris Groenendaal and {Van Bel}, Frank and Sandra Juul and Stephen Back and Frances Northington and Robertson, {Nicola J.} and Carina Mallard and Gunn, {Alistair Jan}",
year = "2012",
month = "5",
doi = "10.1002/ana.22670",
language = "English (US)",
volume = "71",
pages = "589--600",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Cell therapy for neonatal hypoxia-ischemia and cerebral palsy

AU - Bennet, Laura

AU - Tan, Sidhartha

AU - Van Den Heuij, Lotte

AU - Derrick, Matthew

AU - Groenendaal, Floris

AU - Van Bel, Frank

AU - Juul, Sandra

AU - Back, Stephen

AU - Northington, Frances

AU - Robertson, Nicola J.

AU - Mallard, Carina

AU - Gunn, Alistair Jan

PY - 2012/5

Y1 - 2012/5

N2 - Perinatal hypoxic-ischemic brain injury remains a major cause of cerebral palsy. Although therapeutic hypothermia is now established to improve recovery from hypoxia-ischemia (HI) at term, many infants continue to survive with disability, and hypothermia has not yet been tested in preterm infants. There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor cells may have multiple beneficial effects on outcome after hypoxic-ischemic injury. Stem/progenitor cells have shown great promise in animal studies in decreasing neurological impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and method of administration remain surprisingly unclear, and some studies have found no benefit. Although cell-based interventions after completion of the majority of secondary cell death appear to have potential to improve functional outcome for neonates after HI, further rigorous testing in translational animal models is required before randomized controlled trials should be considered.

AB - Perinatal hypoxic-ischemic brain injury remains a major cause of cerebral palsy. Although therapeutic hypothermia is now established to improve recovery from hypoxia-ischemia (HI) at term, many infants continue to survive with disability, and hypothermia has not yet been tested in preterm infants. There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor cells may have multiple beneficial effects on outcome after hypoxic-ischemic injury. Stem/progenitor cells have shown great promise in animal studies in decreasing neurological impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and method of administration remain surprisingly unclear, and some studies have found no benefit. Although cell-based interventions after completion of the majority of secondary cell death appear to have potential to improve functional outcome for neonates after HI, further rigorous testing in translational animal models is required before randomized controlled trials should be considered.

UR - http://www.scopus.com/inward/record.url?scp=84860211612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860211612&partnerID=8YFLogxK

U2 - 10.1002/ana.22670

DO - 10.1002/ana.22670

M3 - Article

C2 - 22522476

AN - SCOPUS:84860211612

VL - 71

SP - 589

EP - 600

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 5

ER -